Antiretroviral News and Research

RSS

AHF calls for reasonable pricing of Gilead’s Quad AIDS drug

Today AIDS Healthcare Foundation, in response to recent press reports regarding drug manufacturer Gilead Sciences, Inc.'s new four-drug HIV/AIDS pill, known as the "Quad," renewed its call for company to price the drug reasonably, particularly in light of the fact that it represents only a marginal improvement over existing medications.

7 Jul 2012

AIDS battle: stretching use of anti-HIV drugs

A Johns Hopkins expert in the drug treatment of HIV disease and AIDS is spearheading an international effort to radically shift the manufacturing and prescribing of combination therapies widely credited in the last decade for keeping the disease in check for 8 million of the 34 million infected people worldwide.

5 Jul 2012

Study examines prevalence of pain among HIV patients in two Ugandan outpatient sites

Sub-Saharan Africa accounts for 69 percent of HIV cases worldwide and 72 percent of AIDS deaths. A study published in The Journal of Pain showed that pain is highly prevalent among well functioning HIV patients in Africa, has a debilitating impact of quality of life, and there is a significant level of unmet need for pain relief.

3 Jul 2012

FDA approves Roche's new HIV viral load test

Roche announced today that a new HIV viral load test has been approved by the United States Food and Drug Administration (FDA) and will be commercially available in the US later this year.

2 Jul 2012

HIV therapy: Interview with Joël Crouzet, CEO of InnaVirVax

HIV therapy has traditionally been associated with antiretrovirals, which considerably reduce the amount of virus present in the blood to nearly undetectable levels.

29 Jun 2012

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

A new once-daily pill combining three antiretrovirals and a booster molecule is a safe and effective alternative to two widely used drug regimens for newly diagnosed HIV-positive adults who have had no previous treatment. The findings of two large international randomised trials published in this week’s Lancet also indicate that the new “Quad” pill is faster acting, doesn’t have the neuropsychiatric side effects associated with other combinations, and could improve compliance with treatment.

29 Jun 2012

Gilead submits elvitegravir NDA with FDA for treatment of HIV-1 infection

Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults.

28 Jun 2012

USA Today features Q&A on Truvada's potential as prevention tool

USA Today features a Q&A on Truvada, an antiretroviral drug that a Food and Drug Administration (FDA) panel in May recommended be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.

27 Jun 2012

U.S. Global AIDS Coordinator discusses lessons learned from U.S. response to HIV/AIDS worldwide

U.S. Global AIDS Coordinator Ambassador Eric Goosby "discussed lessons learned from the U.S. response to the global HIV/AIDS epidemic over the past decade at an event hosted by the Brookings Institute Monday morning," the Center for Global Health Policy's "Science Speaks" blog reports.

27 Jun 2012

Combination regimens trump monotherapy in fight against HIV transmission

A two- or three-drug combination is more effective at reducing intrapartum HIV acquisition than zidovudine monotherapy in babies who are at high risk for transmission, a study in The New England Journal of Medicine shows.

25 Jun 2012

HIV therapy affects bone mass within 2 years

Young men receiving antiretroviral therapy for recently diagnosed HIV are more likely to have low bone mineral density than are other men of a similar age, US researchers report.

25 Jun 2012

WHO releases programmatic update on antiretroviral treatment as prevention of HIV, TB

"The potential for antiretroviral medicine to reduce transmission of HIV and tuberculosis has been demonstrated, but the challenges of using treatment to prevent infection will need to be tackled country by country, and with focus on people for whom it will have the biggest impact, the latest bulletin on HIV treatment from the World Health Organization says," the Center for Global Health Policy's "Science Speaks" blog reports.

20 Jun 2012

Emergence of drug resistance to ARVs has potential to 'curb, and even reverse' gains against HIV

Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.

20 Jun 2012

New, comprehensive approach to treating underserved South Florida patients living with HIV/AIDS

Ushering in a new, comprehensive approach to treating underserved South Florida patients living with HIV/AIDS, the University of Miami Miller School of Medicine has announced a partnership with Magic Johnson Enterprises and Clear Health Alliance, a Medicaid specialty plan offered by Simply Healthcare Plans, a minority owned and operated managed care plan.

19 Jun 2012

Gilead's elvitegravir MAA for HIV-1 infection receives EMA validation

Gilead Sciences, Inc. announced today that its Marketing Authorisation Application (MAA) for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the European Medicines Agency (EMA).

19 Jun 2012

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

InnaVirVax, a biopharmaceutical company specialized in the research and development of therapeutic and diagnostic innovations focused on immune dysregulation, announced today that a new European patent application has been filed on VAC-3S, a “first-in-class” immunotherapy for the treatment of HIV infections.

19 Jun 2012

Less expensive ARV combination just as effective for women in developing countries as costlier ARVs, study shows

A new study by researchers at Brigham and Women's Hospital in Boston shows that the less-expensive antiretroviral nevirapine, when used in combination with other antiretroviral drugs (ARVs), is as effective as a more expensive combination among women in developing countries, VOA News reports.

16 Jun 2012

Changing guidelines threaten important HIV drug trial

In the battle against HIV/AIDS conditions on the frontlines are constantly in flux as treatment, research and policy evolve. The landmark HIV Prevention Trials Network (HPTN) 052 study, which established that antiretroviral treatment in people who are HIV positive decreases the likelihood of transmitting HIV to their sexual partners, was no exception.

15 Jun 2012

Breast milk protects against oral transmission of HIV

More than 15 percent of new HIV infections occur in children. Without treatment, only 65 percent of HIV-infected children will live until their first birthday, and fewer than half will make it to the age of two. Although breastfeeding is attributed to a significant number of these infections, most breastfed infants are not infected with HIV, despite prolonged and repeated exposure.

15 Jun 2012

Brazil's HIV/AIDS treatment, prevention program may be in jeopardy, some experts say

The Miami Herald reports on Brazil's national HIV/AIDS treatment and prevention program, writing, "By the mid-1990s, more effective and powerful antiretroviral therapies replaced the older treatments, and in 1996 Brazil declared that it would offer free antiretroviral treatment to all citizens with AIDS."

14 Jun 2012

Antiretroviral News and Research

AHF calls for reasonable pricing of Gilead’s Quad AIDS drug

AIDS battle: stretching use of anti-HIV drugs

Study examines prevalence of pain among HIV patients in two Ugandan outpatient sites

FDA approves Roche's new HIV viral load test

HIV therapy: Interview with Joël Crouzet, CEO of InnaVirVax

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

Gilead submits elvitegravir NDA with FDA for treatment of HIV-1 infection

USA Today features Q&A on Truvada's potential as prevention tool

U.S. Global AIDS Coordinator discusses lessons learned from U.S. response to HIV/AIDS worldwide

Combination regimens trump monotherapy in fight against HIV transmission

HIV therapy affects bone mass within 2 years

WHO releases programmatic update on antiretroviral treatment as prevention of HIV, TB

Emergence of drug resistance to ARVs has potential to 'curb, and even reverse' gains against HIV

New, comprehensive approach to treating underserved South Florida patients living with HIV/AIDS

Gilead's elvitegravir MAA for HIV-1 infection receives EMA validation

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

Less expensive ARV combination just as effective for women in developing countries as costlier ARVs, study shows

Changing guidelines threaten important HIV drug trial

Breast milk protects against oral transmission of HIV

Brazil's HIV/AIDS treatment, prevention program may be in jeopardy, some experts say

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News